
TL;DR: A 2026 protocol posted to medRxiv describes a nationwide Japan survey designed to measure how dementia specialists handle anti-amyloid antibody therapy, biomarker testing, MRI safety monitoring, service capacity, and patient-choice tradeoffs. Key Findin…
Read article ↗
TL;DR: A 2026 narrative review in the Japanese Journal of Radiology reported that Alzheimer’s brain positron emission tomography (PET) imaging has shifted from supportive diagnosis toward treatment selection because amyloid PET is now central to confirming eli…
Read article ↗
TL;DR: A 2026 systematic review in The Cochrane Database of Systematic Reviews pooled 17 trials of anti-amyloid monoclonal antibodies (N=20,342 people with mild cognitive impairment or mild Alzheimer’s dementia) and concluded that any effect on memory decline…
Read article ↗